Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform
Summary
In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the company’s Board of Directors. “This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. In addition, we expect to realize the tremendous potential of our oncology program, as well as neurology and other areas of significant unmet need.” Joy Ghosh, PhD, of Eventide Asset Management, added, “Biosplice’s alternative splicing platform has enormous potential to address critical needs in osteoarthritis, oncology and neurology, among others. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.